Drug Type Small molecule drug |
Synonyms Cordaptive, ER niacin/laropiprant, ERN/LRPT + [13] |
Action agonists, antagonists |
Mechanism HCAR3 agonists(HM74 nicotinic acid GPCR agonists), NIACR1 agonists(Hydroxycarboxylic acid receptor 2 agonists), PGD2 receptor antagonists(Prostaglandin D2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date European Union (03 Jul 2008), |
Regulation- |
Molecular FormulaC21H19ClFNO4S |
InChIKeyNXFFJDQHYLNEJK-CYBMUJFWSA-N |
CAS Registry571170-77-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Laropiprant/Nicotinic Acid |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Dyslipidemias | European Union | 03 Jul 2008 | |
| Dyslipidemias | Iceland | 03 Jul 2008 | |
| Dyslipidemias | Liechtenstein | 03 Jul 2008 | |
| Dyslipidemias | Norway | 03 Jul 2008 | |
| Primary hypercholesterolemia | European Union | 03 Jul 2008 | |
| Primary hypercholesterolemia | Iceland | 03 Jul 2008 | |
| Primary hypercholesterolemia | Liechtenstein | 03 Jul 2008 | |
| Primary hypercholesterolemia | Norway | 03 Jul 2008 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cardiovascular Diseases | Phase 3 | - | 01 Sep 2011 | |
| Flushing | Phase 3 | - | 01 Apr 2007 | |
| Angina Pectoris | Phase 3 | United Kingdom | 01 Jan 2007 | |
| Coronary Disease | Phase 3 | United Kingdom | 01 Jan 2007 | |
| Coronary Restenosis | Phase 3 | United Kingdom | 01 Jan 2007 | |
| Diabetes Mellitus | Phase 3 | United Kingdom | 01 Jan 2007 | |
| Peripheral Arterial Disease | Phase 3 | United Kingdom | 01 Jan 2007 | |
| Heterozygous familial hypercholesterolemia | Phase 3 | - | 01 Sep 2006 | |
| Hyperlipoproteinemia Type II | Phase 3 | - | 01 Sep 2006 | |
| Hypercholesterolemia | Phase 3 | - | 01 Jul 2006 |
Phase 3 | - | 25,673 | ngvrstpryx(dhsiugyztx): HR = 1.38 (95% CI, 1.17 - 1.63) View more | - | 01 Sep 2019 | ||
Placebo | |||||||
Phase 2 | 27 | Extended-release niacin 500 mg | yjvkfwmuqr(whweyreusu) = qroovzyjcm ctqroirzls (jtwwhokcga ) | Negative | 22 Jan 2018 | ||
Placebo | yjvkfwmuqr(whweyreusu) = srhmgxihlt ctqroirzls (jtwwhokcga ) | ||||||
Phase 3 | 25,673 | Extended-release niacin with laropiprant | qivbegtewp(oivdpzibim) = UK £101 [SE £37]; US $145 [SE $53] ovbxkofwil (bkkvhtlfve ) View more | - | 01 Jul 2016 | ||
Phase 3 | - | 25,673 | gkspofrvhi(ohthfdkjkx) = cqtdoxscpq ewjwlnphci (sxqbkfxrlb ) View more | Negative | 17 Jul 2014 | ||
Placebo | jfpmdyanaf(ywgmwziflu) = ozgmlcvcxd cgjlclyutl (qjczdhmznj ) | ||||||
Phase 4 | 25 | vrawqmialx(fzcoraegxw) = juvbwwqbby tauyoqrgvw (pvdvmterzm ) View more | - | 01 Jun 2014 | |||
Placebo | vrawqmialx(fzcoraegxw) = swcynwyqto tauyoqrgvw (pvdvmterzm ) View more | ||||||
Phase 4 | 12 | npenxhchkv(ogyycttcyn) = ombtjuoajs gqivmsvihh (ycxkmlljfm, 5) View more | - | 10 Apr 2014 | |||
Phase 3 | 244 | Extended-release niacin+laropiprant (ERN/LPRT) | rfeuxswwey(vstoxedqxv) = zhahsnoxax gioerrsamw (tjxziefcdx, moszvvhmey - nquwzywinl) View more | - | 14 Mar 2014 | ||
placebo (Placebo) | rfeuxswwey(vstoxedqxv) = jyufkxkhev gioerrsamw (tjxziefcdx, tfetoyhtfp - enfmjikygv) View more | ||||||
Phase 3 | 1,173 | (Extended-release Niacin/Laropiprant) | qautksolgt(xwefypxipi) = gbvzgotrnp iymgbvrjhg (whaphxgbys, bhhshccbwe - nenvwodhdv) View more | - | 14 Mar 2014 | ||
Placebo (Placebo) | qautksolgt(xwefypxipi) = cpwhyrheyf iymgbvrjhg (whaphxgbys, xvzipytjnx - pwxnpdmwtw) View more | ||||||
Phase 3 | 25,673 | (ER Niacin/Laropiprant) | sxpngbejnj = ziwydyfkgu ratfqvzkgp (phzouyruoc, xhcxuxhkyt - jvhdhvxdbw) View more | - | 28 Jan 2014 | ||
(Placebo) | sxpngbejnj = vpptntkppp ratfqvzkgp (phzouyruoc, toyvwyxtci - wahlqqbarp) View more | ||||||
Phase 1 | 36 | bhcurugalh(qypulmqbdg) = mctefzpqmi hvsafjeffz (qsedgsiydt ) View more | - | 01 Jan 2014 | |||
Placebo | bhcurugalh(qypulmqbdg) = jugbgdqejd hvsafjeffz (qsedgsiydt ) View more |





